New corporate contracts drive SmithKline's laboratory sales
This article was originally published in Clinica
Executive Summary
SmithKline Beecham's clinical laboratory division registered second-quarter sales of £228 million ($376 million), up 9% on the same period in the previous year. On a comparable basis this is a rise of 11%. The company attributes this mainly to volume growth, which was primarily generated from new corporate contracts.